Fig. 2From: Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patientsProportion of ≥ 30%, ≥ 50%, ≥ 75% and 100% responders after 3 (M3) and 6 months (M6). M3 = month 3; M6 = month 6Back to article page